National Cancer Institute National Cancer Institute
U.S. National Institutes of Health National Cancer Institute
NCI Home Cancer Topics Clinical Trials Cancer Statistics Research & Funding News About NCI
Myelodysplastic Syndromes Treatment (PDQ®)
Patient VersionHealth Professional VersionEn españolLast Modified: 11/06/2008
Myelodysplastic Syndromes: Comparison of the FAB and WHO Classifications

FAB (1982)  WHO (1997) 
Myelodysplastic Syndromes Myelodysplastic Syndromes
Refractory anemia Refractory anemia
Refractory cytopenia with multilineage dysplasia
Refractory anemia with ringed sideroblasts Refractory anemia with ringed sideroblasts
Refractory anemia with excess blasts Refractory anemia with excess blasts
Myelodysplastic syndrome, unclassifiable
Myelodysplastic syndrome associated with del(5q)
Reclassified from MDS to:
Refractory anemia with excess blasts in transformation Acute Myeloid Leukemia identified as, AML with multilineage dysplasia following a myelodysplastic syndrome
Chronic myelomonocytic leukemia Myelodysplastic and Myeloproliferative Diseases


A Service of the National Cancer Institute
Department of Health and Human Services National Institutes of Health USA.gov